|Awarded On||February 19, 2020|
|Title||Clinical MR Spectroscopy Development of Malignancy Biomarkers in Gliomas|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Changho Choi|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Magnetic resonance spectroscopy (MRS) is uniquely capable of measuring biochemicals in the human body noninvasively and thus widely used for evaluating molecular changes in brain tumors. MRS identification of 2-hydroxyglutarate (2HG) in isocitrate dehydrogenase (IDH) mutant gliomas provides the first in vivo imaging biomarker specific to a genetic mutation, making the diagnosis of IDH mutant gliomas possible without surgery. 2HG also has significant predictive value with respect to the stage and survival in gliomas because an IDH mutation carries a favorable prognosis. Following our 2HG MRS development (Choi et al. Nat Med 2012), we translated the MRS protocol into clinical MR scanners world...